Kane Biotech Inc. (CVE:KNE – Get Free Report) shares traded up 28.6% on Friday . The company traded as high as C$0.05 and last traded at C$0.05. 1,505,028 shares traded hands during trading, an increase of 380% from the average session volume of 313,629 shares. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The firm has a market capitalization of C$7.53 million, a P/E ratio of -0.56 and a beta of 0.60. The stock’s 50 day simple moving average is C$0.04 and its 200 day simple moving average is C$0.04. The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- Wall Street Alert: Buy AES
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
